5 Key Takeaways

• 1

  Ali Tavassoli received the Royal Society of Chemistry's Interdisciplinary Prize and was named on the Medicine Maker Power List 2025.

• 2

  The biopharma industry is expanding its definition of druggable targets, including previously inaccessible proteins and interactions.

• 3

  A significant bottleneck in drug development is the mismatch between scientific timelines and venture capital funding cycles.

• 4

  Tavassoli argues that the belief that peptides cannot be oral drugs is outdated, citing advancements in cyclic peptide design.

• 5

  He advocates for stronger pull incentives to address market failures in drug development for areas like antimicrobial resistance.